October 20, 2021 8:00am

It’s a feeling, maybe a belief that one can rely on someone, something or markets – don’t; when you have doubts, there is no doubt

Pre-open indications: 2 SELLs, and 4 BUYs with 1 Pump (or No Promote)

What I provide is an intelligence daily. RMi outlines the prelude to the daily dose of facts and objectivity! My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.

Dow futures are DOWN -0.05% (-16 points), S&P futures are DOWN -0.06% (-2.50 point) and NASDAQ futures are DOWN -0.04% (+6 point)

 

U.S. stock index futures were floating down slowly on Wednesday,

European stocks were subdued amid more mixed sentiment globally overnight,

Asia-Pacific stocks were mixed as China kept its benchmark lending rate unchanged while Japan climbed.

 

Henry’omics:

The Dow advanced 0.56%, on Tuesday for its third positive session in the last four days while the S&P 500 added 0.74%, while the Nasdaq advanced 0.71%.

The S&P and Nasdaq saw their fifth straight day of gains, the longest daily winning streak since late August.

The major averages are approaching their all-time highs. The Dow is 0.49% below its record, while the S&P and Nasdaq sit 0.58% and 1.78% below their highwater marks.

It’s time to say a quick good bye to return later …

 

Interesting note: The FDA May Approve ‘Mix-and-Match’ Booster Shots as Soon as This Week

  • The FDA is moving to soon allow people to have a Covid-19 booster shot different from the vaccine they initially received, according to reports.

 

If you didn’t remember what happen at Tuesday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

Q4: October, 7 positive and 6 negative closes

Q3/21:

  • September, 1 holiday, 10 positive and 10 negative close
  • August - 12 positive and 10 negative close
  • July: 6 positives, 1 holiday and 15 negative closes

 

Companies in my headlights – It’s your decision; I provide an idea and context:

SELL with a Pump or no promote:

Biostage (BSTG) closed flat at $3.00 with 1,488 shares traded after Monday’s -$0.065 with 4,041 shares traded, Friday’s -$0.035 with 528 shares traded, Thursday’s flat at $3.13 with 22 shares traded after last Wednesday’s +$0.09 with 3,492 shares traded – WOW.

  • For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation. What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?

 

BUY:

Cellectis SA (CLLS) closed up +$0.32 to $10.82 with a positive +$0.21 or +1.94% pre-open indication,

Intellia Therapeutics (NTLA) closed up +$1.85 to $132.68 after Monday’s +$0.34 to $130.83 fallowing Friday -$1.28 to $130.49 and has a positive +$0.83 or +0.63% pre-open indication.

Fate Therapeutics (FATE) closed up +$1.06 to $61.17 with a positive +$0.33 or +0.54% pre-open indication,

CRISPR Therapeutics (CRSP) closed up +$4.05 to $100.26 after Monday’s -$0.79 to $96.21, Friday’s +$0.23 to $97.00, Thursday’s +$1.93 to $98.70 and last Wednesday’s -$5.82 with a positive +$1.73 or +1.73% pre-market indication.

 

SELL:

BioLife Solutions (BLFS) closed up +$0.46 to $42.07 with a negative +$0.03 or +0.07% pre-open indication,

 

SELL from BUY:

bluebird bio (BLUE) closed up +$0.46 to $21.49 with a negative -$0.07 or -0.33% pre-open indication,

 

The BOTTOM LINE: time to profit …before declines …!

As I previously stated, “The major averages are approaching their all-time highs. The Dow is 0.49% below its record, while the S&P and Nasdaq sit 0.58% and 1.78% below their highwater marks.

It’s time to say a quick good bye to return later …

The stem, cell and gene therapy earnings will be beginning 10/28 Thursday with Alnylam Pharmaceuticals leading the releases with Athersys ATHX) coming 11/15 (to date).

Theme is too much uncertainty I between, what’s more likely to me is skepticism …

Sector stocks have traded choppily over the past several weeks as investors contemplated the implications of ongoing price increases (i.e., inflation) against a backdrop of decelerating economic growth.

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.